Targeting S100A1 in heart failure

Gene Therapy

Volumn 19, Issue 6, 2012, Pages 613-621

  Ritterhoff, J ^a   Most, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

calcium; heart failure; S100A1; sarcoplasmic reticulum

Indexed keywords

ADENOVIRUS VECTOR; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM BINDING PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; PROTEIN S100A1; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

CALCIUM TRANSPORT; CELLULAR DISTRIBUTION; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DRUG POTENTIATION; GENE ACTIVATION; GENE DOSAGE; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; ISCHEMIC CARDIOMYOPATHY; MITOCHONDRION; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SARCOMERE; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; GENE TARGETING; GENE THERAPY; HEART FAILURE; HUMANS; MICE; S100 PROTEINS;

ANIMALIA;

EID: 84862012200     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.8     Document Type: Review

References (70)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. WHO. Fact Sheet No. 317, 2011.
3. Margulies KB, Bednarik DP, Dries DL. Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol 2009; 53: 1752-1759. Review.
4. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res 2003; 92: 350-358. (Pubitemid 36298194)
5. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79. (Pubitemid 38249147)
6. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
7. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol 2003; 41: 1606-1610. (Pubitemid 36543382)
8. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008; 102: 1458-1470.
9. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008; 70: 23-49. (Pubitemid 351738170)
10. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000; 86: 616-621. (Pubitemid 30208427)
11. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
12. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450: 191-231. (Pubitemid 29295473)
13. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-1122. (Pubitemid 39164640)
14. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7: d1356-d1368.
15. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008; 34: 357-364. (Pubitemid 351381290)
16. Zimmer DB, Chaplin J, Baldwin A, Rast M. S100-mediated signal transduction in the nervous system and neurological diseases. Cell Mol Biol (Noisy-le-grand) 2005; 51: 201-214. (Pubitemid 43086295)
17. Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB et al. The threedimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. J Mol Biol 2005; 353: 410-426. (Pubitemid 41356621)
18. Rustandi RR, Baldisseri DM, Inman KG, Nizner P, Hamilton SM, Landar A et al. Three-dimensional solution structure of the calcium-signaling protein apo-S100A1 as determined by NMR. Biochemistry 2002; 41: 788-796. (Pubitemid 34061979)
19. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540-551.
20. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and-independent interactions of the S100 protein family. Biochem J 2006; 396: 201-214. (Pubitemid 43837235)
21. Osterloh D, Ivanenkov VV, Gerke V. Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization. Cell Calcium 1998; 24: 137-151. (Pubitemid 28470431)
22. Zimmer DB, Wright Sadosky P, Weber DJ. Molecular mechanisms of S100-target protein interactions. Microsc Res Tech 2003; 60: 552-559.
23. Goch G, Vdovenko S, Kozlowska H, Bierzynski A. Affinity of S100A1 protein for calcium increases dramatically upon glutathionylation. FEBS J 2005; 272: 2557-2565. (Pubitemid 40705075)
24. Wright NT, Cannon BR, Zimmer DB, Weber DJ. S100A1: structure, function, and therapeutic potential. Curr Chem Biol 2009; 3: 138-145.
25. Zhukova L, Zhukov I, Bal W, Wyslouch-Cieszynska A. Redox modifications of the C-terminal cysteine residue cause structural changes in S100A1 and S100B proteins. Biochim Biophys Acta 2004; 1742: 191-201. (Pubitemid 39601780)
26. Rohde D, Ritterhoff J, Voelkers M, Katus HA, Parker TG, Most P. S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res 2010; 3: 525-537.
27. Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009; 47: 445-455.
28. Volkers M, Rohde D, Goodman C, Most P. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol 2010; 2010: 178614.
29. Kato K, Kimura S. S100ao (alpha alpha) protein is mainly located in the heart and striated muscles. Biochim Biophys Acta 1985; 842: 146-150. (Pubitemid 15239658)
30. Kiewitz R, Lyons GE, Schafer BW, Heizmann CW. Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim Biophys Acta 2000; 1498: 207-219.
31. Haimoto H, Kato K. S100a0 (alpha alpha) protein in cardiac muscle. Isolation from human cardiac muscle and ultrastructural localization. Eur J Biochem 1988; 171: 409-415. (Pubitemid 18042907)
32. Ehlermann P, Remppis A, Guddat O, Weimann J, Schnabel PA, Motsch J et al. Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. Biochim Biophys Acta 2000; 1500: 249-255. (Pubitemid 30060397)
33. Zimmer DB, Song W, Zimmer WE. Isolation of a rat S100 alpha cDNA and distribution of its mRNA in rat tissues. Brain Res Bull 1991; 27: 157-162.
34. Kato K, Kimura S, Haimoto H, Suzuki F. S100a0 (alpha alpha) protein: distribution in muscle tissues of various animals and purification from human pectoral muscle. J Neurochem 1986; 46: 1555-1560. (Pubitemid 16062560)
35. Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, Berzins B et al. Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 2008; 102: 786-794. (Pubitemid 351521593)
36. Desjardins JF, Pourdjabbar A, Quan A, Leong-Poi H, Teichert-Kuliszewska K, Verma S et al. Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H1457-H1465.
37. Lefranc F, Decaestecker C, Brotchi J, Heizmann CW, Dewitte O, Kiss R et al. Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta,-eta and-zeta) in a rat model of cerebral basilar artery vasospasm. Neuropathol Appl Neurobiol 2005; 31: 649-660. (Pubitemid 41668375)
38. Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004; 114: 1550-1563. (Pubitemid 40385546)
39. Kiewitz R, Acklin C, Schafer BW, Maco B, Uhrik B, Wuytack F et al. Ca2+-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+-ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun 2003; 306: 550-557. (Pubitemid 36683110)
40. Kettlewell S, Most P, Currie S, Koch WJ, Smith GL. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol 2005; 39: 900-910. (Pubitemid 41572323)
41. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 2005; 118: 421-431. (Pubitemid 40277353)
42. Most P, Remppis A, Pleger ST, Loffler E, Ehlermann P, Bernotat J et al. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 2003; 278: 33809-33817. (Pubitemid 37553215)
43. Most P, Seifert H, Gao E, Funakoshi H, Volkers M, Heierhorst J et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006; 114: 1258-1268. (Pubitemid 44402051)
44. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 2001; 98: 13889-13894. (Pubitemid 33115994)
45. Volkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge BR, Jr., Wegner FV et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2007; 41: 135-143. (Pubitemid 46014745)
46. Treves S, Scutari E, Robert M, Groh S, Ottolia M, Prestipino G et al. Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry 1997; 36: 11496-11503. (Pubitemid 27408633)
47. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007; 27: 4365-4373. (Pubitemid 46906561)
48. Leyva JA, Bianchet MA, Amzel LM. Understanding ATP synthesis: structure and mechanism of the F1-ATPase (Review). Mol Membr Biol 2003; 20: 27-33. (Pubitemid 36460643)
49. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol 2002; 34: 1259-1271. (Pubitemid 35244399)
50. Yamasaki R, Berri M, Wu Y, Trombitas K, McNabb M, Kellermayer MS et al. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys J 2001; 81: 2297-2313. (Pubitemid 32917177)
51. Fukushima H, Chung CS, Granzier H. Titin-isoform dependence of titin-actin interaction and its regulation by S100A1/Ca2+ in skinned myocardium. J Biomed Biotechnol 2010; 2010: 727239.
52. Maco B, Mandinova A, Durrenberger MB, Schafer BW, Uhrik B, Heizmann CW. Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human heart. Physiol Res 2001; 50: 567-574. (Pubitemid 34087275)
53. LeWinter MM, Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role in disease. Clin Chim Acta 2007; 375: 1-9. (Pubitemid 44584235)
54. Remppis A, Most P, Loffler E, Ehlermann P, Bernotat J, Pleger S et al. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002; 97 (Suppl 1): I56-I62.
55. Brezova A, Heizmann CW, Uhrik B. Immunocytochemical localization of S100A1 in mitochondria on cryosections of the rat heart. Gen Physiol Biophys 2007; 26: 143-149. (Pubitemid 47422813)
56. Remppis A, Greten T, Schafer BW, Hunziker P, Erne P, Katus HA et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996; 1313: 253-257. (Pubitemid 26342956)
57. Brinks H, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011; 58: 966-973.
58. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger Wet al. Stable myocardialspecific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007; 115: 2506-2515. (Pubitemid 46763224)
59. Pleger ST, Most P, Heidt B, Voelkers M, Hata JA, Katus HA et al. S100A1 gene transfer in myocardium. Eur J Med Res 2006; 11: 418-422. (Pubitemid 44768535)
60. Pleger ST, Remppis A, Heidt B, Volkers M, Chuprun JK, Kuhn M et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 2005; 12: 1120-1129. (Pubitemid 41723046)
61. Pleger STSC, Kziencek J, Mueller O, Bekeredjian R, Remppis A et al. Retroinfusionfacilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically relevant pig heart failure model. Circulation 2008; 118: S792.
62. Du XJ, Cole TJ, Tenis N, Gao XM, Kontgen F, Kemp BE et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol 2002; 22: 2821-2829. (Pubitemid 34263002)
63. Ackermann GE, Domenighetti AA, Deten A, Bonath I, Marenholz I, Pedrazzini T et al. S100A1 deficiency results in prolonged ventricular repolarization in response to sympathetic activation. Gen Physiol Biophys 2008; 27: 127-142.
64. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 1998; 39: 60-76. (Pubitemid 28322380)
65. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B et al. Animal models of cardiovascular diseases. J Biomed Biotechnol 2011; 2011: 497841.
66. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3: 92ra64.
67. Belmonte SL, Margulies KB, Blaxall BC. S100A1: another step toward therapeutic development for heart failure. J Am Coll Cardiol 2011; 58: 974-976.
68. Raake PW, Tscheschner H, Reinkober J, Ritterhoff J, Katus HA, Koch WJ et al. Gene therapy targets in heart failure: the path to translation. Clin Pharmacol Ther 2011; 90: 542-553.
69. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 2011; 57: 1169-1180.
70. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.